Hutchison MediPharma's Cancer Drug Meets Endpoint in Phase II Trial

Shanghai's Hutchison MediPharma, the drug discovery arm of Chi-Med, reported that fruquintinib met its primary endpoint -- progression-free survival -- in a China trial conducted among heavily pre-treated patients with metastatic colorectal cancer. Two years ago, the company out-licensed China rights for the drug to Lilly in an $87 million deal. MediPharma is continuing to assess data from secondary endpoints, though it said all the results appear to be in-line with expectations. More details.... Stock Symbol: (AIM: HCM) (NYSE: LLY) Share this with colleagues: // //